
Gian Luca De Salvo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1173768/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Clinical Cancer Research, 2022, 28, 308-317.	7.0	36
2	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro-Oncology, 2021, 23, 264-276.	1.2	48
3	Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. Pediatric Blood and Cancer, 2021, 68, e28832.	1.5	13
4	Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience. European Journal of Cancer, 2021, 146, 21-29.	2.8	20
5	Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG). The Lancet Child and Adolescent Health, 2021, 5, 546-558.	5.6	28
6	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). European Journal of Cancer, 2021, 155, 179-190.	2.8	13
7	A new standard of care for patients with high-risk rhabdomyosarcoma? – Authors' reply. Lancet Oncology, The, 2020, 21, e3.	10.7	2
8	Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. Cancer, 2020, 126, 823-831.	4.1	21
9	Colonic J-Pouch or Straight Colorectal Reconstruction After Low Anterior Resection For Rectal Cancer: Impact on Quality of Life and Bowel Function: A Multicenter Prospective Randomized Study. Diseases of the Colon and Rectum, 2020, 63, 1511-1523.	1.3	21
10	Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. Lancet 2020;395:1208–16. European Urology Oncology, 2020, 3, 713.	5.4	2
11	Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSGâ€RMS2005 study. Cancer Medicine, 2020, 9, 7580-7589.	2.8	16
12	Paratesticular rhabdomyosarcoma—Impact of locoregional approach on patient outcome: A report from the European paediatric Soft tissue sarcoma Study Group (EpSSG). Pediatric Blood and Cancer, 2020, 67, e28479.	1.5	13
13	Dermatofibrosarcoma protuberans in children and adolescents: The European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Pediatric Blood and Cancer, 2020, 67, e28351.	1.5	11
14	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. Clinical Cancer Research, 2020, 26, 4478-4484.	7.0	20
15	Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). European Journal of Cancer, 2020, 127, 123-129.	2.8	71
16	Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. European Journal of Cancer, 2020, 130, 72-80.	2.8	18
17	Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma. Clinical Cancer Research, 2020, 26, 2921-2931.	7.0	8
18	Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTSâ€2005 prospective study. Pediatric Blood and Cancer, 2019, 66, e27833.	1.5	40

#	Article	IF	CITATIONS
19	Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 1566-1575.	10.7	161
20	Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group. Journal of Clinical Oncology, 2019, 37, 723-730.	1.6	24
21	Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials. European Journal of Cancer, 2019, 112, 98-106.	2.8	21
22	Self-efficacy for coping: utility of the Cancer behavior inventory (Italian) for use in palliative care. BMC Palliative Care, 2019, 18, 34.	1.8	18
23	Outcome of localized liverâ€bile duct rhabdomyosarcoma according to local therapy: A report from the European Paediatric Softâ€Tissue Sarcoma Study Group (EpSSG)â€RMS 2005 study. Pediatric Blood and Cancer, 2019, 66, e27725.	1.5	11
24	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. Oncologist, 2019, 24, 1424-1431.	3.7	22
25	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 110-119.	10.7	238
26	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients Journal of Clinical Oncology, 2019, 37, 2045-2045.	1.6	2
27	Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience. Cancer Medicine, 2018, 7, 1384-1393.	2.8	22
28	Pediatric patients with cutaneous melanoma: A European study. Pediatric Blood and Cancer, 2018, 65, e26974.	1.5	26
29	Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005). Pediatric Blood and Cancer, 2018, 65, e26942.	1.5	21
30	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncology, The, 2018, 19, 27-39.	10.7	717
31	First Prospective Multicenter Italian Study on the Impact of the 21â€Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. Oncologist, 2018, 23, 297-305.	3.7	8
32	Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. Journal of Clinical Oncology, 2018, 36, 3466-3476.	1.6	21
33	Fusion status in patients with lymph nodeâ€positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer, 2018, 124, 3201-3209.	4.1	51
34	Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups. Pediatric Blood and Cancer, 2018, 65, e27096.	1.5	40
35	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq1 1 (19, 1061-1071.	0.784314 10.7	rgBT /Overloc 137
36	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS) Journal of Clinical Oncology, 2018, 36, 2047-2047.	1.6	4

#	Article	IF	CITATIONS
37	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study Journal of Clinical Oncology, 2018, 36, 507-507.	1.6	6
38	Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) Journal of Clinical Oncology, 2018, 36, LBA2-LBA2.	1.6	23
39	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results Journal of Clinical Oncology, 2018, 36, e24074-e24074.	1.6	0
40	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. Clinical Cancer Research, 2017, 23, 3316-3324.	7.0	43
41	Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children's Oncology Group. European Journal of Cancer, 2017, 78, 1-6.	2.8	62
42	The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. The Lancet Child and Adolescent Health, 2017, 1, 284-292.	5.6	43
43	A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (â‰≇6Âyears) low grade glioma– A final report. European Journal of Cancer, 2017, 81, 206-225.	2.8	104
44	Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatric Blood and Cancer, 2017, 64, e26348.	1.5	32
45	Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells. Oncotarget, 2017, 8, 6433-6445.	1.8	29
46	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS) Journal of Clinical Oncology, 2017, 35, TPS2085-TPS2085.	1.6	3
47	First prospective multicenter Italian study on the impact of the 21-Gene Recurrence Score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients Journal of Clinical Oncology, 2017, 35, e12038-e12038.	1.6	0
48	Genomic index in pediatric synovial sarcoma (SYNOBIO study): The European Pediatric Soft Tissue Sarcoma Group (EpSSG) experience Journal of Clinical Oncology, 2017, 35, 10529-10529.	1.6	0
49	First prospective multicenter Italian study on the impact of the 21-gene recurrence score® (RS) in adjuvant clinical decisions for ER + /HER2- early breast cancer patients. Annals of Oncology, 2016, 27, vi53.	1.2	Ο
50	Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. European Journal of Surgical Oncology, 2016, 42, 1914-1923.	1.0	89
51	Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study—EpSSG NRSTS 2005. European Journal of Cancer, 2016, 60, 69-82.	2.8	63
52	Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study GroupAexperience. European Journal of Cancer, 2016, 57, 1-9.	2.8	94
53	Childhood Leukemia and 50 Hz Magnetic Fields: Findings from the Italian SETIL Case-Control Study. International Journal of Environmental Research and Public Health, 2015, 12, 2184-2204.	2.6	25
54	Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Annals of Oncology, 2015, 26, 567-572.	1.2	115

#	Article	IF	CITATIONS
55	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. British Journal of Cancer, 2014, 111, 25-32.	6.4	41
56	Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. Annals of Oncology, 2014, 25, 231-236.	1.2	61
57	Adrenocortical tumors in Italian children: Analysis of clinical characteristics and P53 status. Data from the national registries. Journal of Pediatric Surgery, 2014, 49, 1367-1371.	1.6	42
58	Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience. Journal of Pediatrics, 2014, 164, 376-382.e2.	1.8	47
59	A multidisciplinary approach to improve preoperative understanding and reduce anxiety. European Journal of Anaesthesiology, 2013, 30, 734-742.	1.7	34
60	Survivin Expression and Prognostic Significance in Pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS ONE, 2013, 8, e80456.	2.5	19
61	Synovial sarcoma in children and adolescents: A critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosis. European Journal of Cancer, 2012, 48, 1370-1375.	2.8	25
62	Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. European Journal of Cancer, 2012, 48, 3448-3455.	2.8	41
63	The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: the Italian pediatric oncology view. Expert Review of Anticancer Therapy, 2012, 12, 243-254.	2.4	16
64	Clinical and molecular detection of inherited colorectal cancers in northeast Italy. Tumor Biology, 2012, 33, 857-864.	1.8	3
65	DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma. Cancer Letters, 2011, 310, 84-93.	7.2	15
66	Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. European Journal of Cancer, 2011, 47, 724-731.	2.8	123
67	Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy. Pigment Cell and Melanoma Research, 2011, 24, 728-730.	3.3	12
68	Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. British Journal of Cancer, 2011, 104, 1816-1821.	6.4	53
69	Psychological wellâ€being outcomes in diseaseâ€free survivors of midâ€ŀow rectal cancer following curative surgery. Psycho-Oncology, 2011, 20, 706-714.	2.3	21
70	Inflammatory myofibroblastic tumors in childhood. Cancer, 2010, 116, 216-226.	4.1	71
71	Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. Supportive Care in Cancer, 2010, 18, 601-608.	2.2	50
72	Pancreatic tumors in children and adolescents: The Italian TREP project experience. Pediatric Blood and Cancer, 2010, 54, 675-680.	1.5	75

#	Article	IF	CITATIONS
73	Evaluating access to pediatric cancer care centers of children and adolescents with rare tumors in Italy: The TREP project. Pediatric Blood and Cancer, 2009, 53, 152-155.	1.5	52
74	Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution's Experience with 52 Patients. Annals of Surgical Oncology, 2009, 16, 191-199.	1.5	256
75	Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI). Annals of Surgical Oncology, 2009, 16, 2018-2027.	1.5	121
76	Family History of Cancer Rather Than p53 Status Predicts Efficacy of Pegylated Liposomal Doxorubicin and Oxaliplatin in Relapsed Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1022-1028.	2.5	10
77	Local lymph node involvement in pediatric renal cell carcinoma: A report from the Italian TREP project. Pediatric Blood and Cancer, 2008, 51, 475-478.	1.5	39
78	Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph Node. Annals of Surgical Oncology, 2008, 15, 1202-1210.	1.5	64
79	Health-Related Quality of Life Outcomes in Disease-Free Survivors of Mid-Low Rectal Cancer After Curative Surgery. Annals of Surgical Oncology, 2008, 15, 1846-1854.	1.5	50
80	Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella–GIVOM Italian randomised clinical trial. European Journal of Surgical Oncology, 2008, 34, 508-513.	1.0	175
81	Clinical impact of false-negative sentinel lymph nodes in breast cancer. European Journal of Surgical Oncology, 2008, 34, 620-625.	1.0	31
82	A Randomized Clinical Trial on Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection in Breast Cancer. Annals of Surgery, 2008, 247, 207-213.	4.2	277
83	Which benefit from adding gemcitabine to vinorelbine in elderly (≥70 years) women with metastatic breast cancer? Early interruption of a phase II study. Annals of Oncology, 2007, 18, 58-63.	1.2	19
84	The challenge of very rare tumours in childhood: The Italian TREP project. European Journal of Cancer, 2007, 43, 654-659.	2.8	98
85	Predictors of unresectability in hepatoblastoma: A 20-year single centre report. Digestive and Liver Disease, 2007, 39, A69.	0.9	Ο
86	Features predicting unresectability in hepatoblastoma. Cancer, 2007, 110, 1050-1058.	4.1	36
87	Prognostic factors in pleuro-pulmonary blastoma. Pediatric Blood and Cancer, 2007, 48, 318-323.	1.5	62
88	Contribution of SLN investigation with 99mTc-nanocolloid in clinical staging of thyroid cancer: technical feasibility. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 934-938.	6.4	22
89	Association Between MDM2–SNP309 and Age at Colorectal Cancer Diagnosis According to p53 Mutation Status. Journal of the National Cancer Institute, 2006, 98, 285-288.	6.3	123
90	Sentinel node mapping andÂbiopsy inÂthyroid cancer: aÂsurgical perspective. Biomedicine and Pharmacotherapy, 2006, 60, 405-408.	5.6	29

#	Article	IF	CITATIONS
91	Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. European Journal of Surgical Oncology, 2006, 32, 1201-1208.	1.0	36
92	5-Fluorouracil and Weekly Oxaliplatin Combined with Radiotherapy for Locally Advanced Rectal Cancer: Surgical Complications and Long-term Results. Archives of Medical Research, 2006, 37, 860-865.	3.3	10
93	Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]. BMC Cancer, 2006, 6, 44.	2.6	22
94	Predicting Tumor Outcome following Cancer Vaccination by Monitoring Quantitative and Qualitative CD8+ T Cell Parameters. Journal of Immunology, 2006, 176, 1999-2006.	0.8	14
95	The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI). Journal of Nuclear Medicine, 2006, 47, 234-41.	5.0	31
96	The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. Melanoma Research, 2005, 15, 191-198.	1.2	34
97	Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas. Annals of Surgical Oncology, 2005, 12, 398-405.	1.5	41
98	Insufficient evidence to compare clinical effectiveness and safety of self-expanding metal stents with other treatments for malignant colorectal obstruction. Cancer Treatment Reviews, 2005, 31, 226-229.	7.7	0
99	Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients. European Journal of Surgical Oncology, 2005, 31, 715-720.	1.0	61
100	Sentinel node biopsy for breast cancer: is it already a standard of care? A survey of current practice in an Italian region. BMC Cancer, 2004, 4, 2.	2.6	9
101	Number of Metastatic Sentinel Nodes As Predictor of Axillary Involvement in Patients with Breast Cancer. Breast Cancer Research and Treatment, 2004, 86, 171-179.	2.5	27
102	Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas. Cancer, 2004, 101, 1664-1671.	4.1	113
103	Analysis of technical and clinical variables affecting sentinel node localization in patients with breast cancer after a single intradermal injection of 99mTc nanocolloidal albumin. Nuclear Medicine Communications, 2004, 25, 1119-1124.	1.1	14
104	Curative surgery for obstruction from primary left colorectal carcinoma: Primary or staged resection?. The Cochrane Library, 2004, , CD002101.	2.8	67
105	Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. European Journal of Cancer, 2003, 39, 1577-1585.	2.8	56
106	Sentinel-Node Biopsy in Breast Cancer. New England Journal of Medicine, 2003, 349, 1968-1971.	27.0	11
107	Phase I–II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities. Melanoma Research, 2003, 13, 293-297.	1.2	4
108	Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Letters, 2001, 168, 31-36.	7.2	49

7

#	Article	IF	CITATIONS
109	Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. Aids, 2000, 14, 1721-1729.	2.2	44
110	The unconventional Di Bella cancer treatment. , 1999, 86, 1903-1911.		10
111	Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. , 1998, 54, 7-11.		3
112	Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut, 1998, 42, 856-860.	12.1	81
113	A model to predict long-term sustained response to interferon therapy in chronic hepatitis C. Journal of Viral Hepatitis, 1997, 4, 193-197.	2.0	2
114	Therapy of hepatitis C: Re-treatment with alpha interferon. Hepatology, 1997, 26, 137S-142S.	7.3	96